Immuneel Therapeutics Pvt. Ltd. has announced a strategic collaboration with the Tata Memorial Centre (TMC) to advance Cell & Gene Therapy (CGT) research and development in India.
This partnership integrates TMC’s world-renowned clinical and translational research expertise with Immuneel’s robust capabilities in cell therapy development, GMP manufacturing, regulatory sciences, and commercialization. Together, the organizations aim to accelerate the next generation of advanced therapies, establishing India as a global hub for CGT innovation.
The collaboration focuses on key strategic objectives, including strengthening translational research, accelerating the development of innovative CGT platforms, and expanding institutional capabilities across clinical research, manufacturing, and scientific training. Ultimately, the alliance seeks to foster collaborative innovation to significantly improve patient outcomes and expand access to life-saving treatments.
“At Immuneel, we believe that meaningful progress in advanced therapies is built on strong partnerships between clinicians, researchers, academia, and industry,” the company stated, emphasizing a shared commitment to making cutting-edge care accessible. Both leadership teams look forward to shaping the future of cancer care through science and collaboration.
Written by: Pragna Biswas
Graphics by: Pramit Hazra
